Insiders who purchased Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) shares in the past 12 months are unlikely to be deeply impacted by the stock's 16% decline over the past week. After taking the recent loss into consideration, the US$1.03m worth of stock they bought is now worth US$2.35m, indicating that their investment yielded a positive return.

While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders are doing.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

Corvus Pharmaceuticals Insider Transactions Over The Last Year

Over the last year, we can see that the biggest insider purchase was by Co-Founder Richard Miller for US$1m worth of shares, at about US$1.73 per share. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of US$3.93. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive.

Corvus Pharmaceuticals insiders may have bought shares in the last year, but they didn't sell any. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

View our latest analysis for Corvus Pharmaceuticals

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying.

Insider Ownership Of Corvus Pharmaceuticals

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. We usually like to see fairly high levels of insider ownership. Our data suggests Corvus Pharmaceuticals insiders own 0.7% of the company, worth about US$1.9m. I generally like to see higher levels of ownership.

What Might The Insider Transactions At Corvus Pharmaceuticals Tell Us?

There haven't been any insider transactions in the last three months -- that doesn't mean much. On a brighter note, the transactions over the last year are encouraging. While we have no worries about the insider transactions, we'd be more comfortable if they owned more Corvus Pharmaceuticals stock. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Corvus Pharmaceuticals. To help with this, we've discovered 3 warning signs (2 are a bit concerning!) that you ought to be aware of before buying any shares in Corvus Pharmaceuticals.

But note: Corvus Pharmaceuticals may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.